Vertex stock price target maintained at $641 by H.C. Wainwright

H.C. Wainwright has maintained a Buy rating on Vertex shares (NASDAQ:VRTX) and kept its price target at $641.00. The stock is trading at $523.42, and analyst consensus supports this price target, with a high target of $672. Vertex's AMPLIFIED Cohort 1 data showed a 42.7% reduction in UACR, which falls within the firm's 30-40% expectation range.

This result validates their thesis about APOL1 inhibition retaining activity below AMPLITUDE's severe-proteinuria entry floor. The data also strengthens the potential of inaxaplin across the broader AMKD spectrum and boosts the total addressable market. Vertex's AMPLIFIED Cohort 2 showed a 17.3% reduction, below its minimum expectation of 22%, but the firm believes trial design and biomarkers can address this issue.

This positive development aligns with Vertex's strong market cap of $132.3 billion and a 33% return over the past year. Analysts like BMO Capital, Stifel, RBC Capital, Bernstein SocGen Group, and Bank of America have all reconfirmed their positive outlook on Vertex, with price targets ranging from $570 to $608.